Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Neurology and Neuroscience Reports
Published in: Current Neurology and Neuroscience Reports 12/2023

10-11-2023 | Long-COVID Syndrome | Review

Autonomic Manifestations of Long-COVID Syndrome

Authors: Rashmin Hira, Kavithra Karalasingham, Jacquie R. Baker, Satish R. Raj

Published in: Current Neurology and Neuroscience Reports | Issue 12/2023

Login to get access

Abstract

Purpose of Review

Long-COVID is a novel condition emerging from the COVID-19 pandemic. Long-COVID is characterized by symptoms commonly seen in autonomic disorders including fatigue, brain fog, light-headedness, and palpitations. This article will critically evaluate recent findings and studies on Long-COVID and its physiological autonomic manifestations.

Recent Findings

Studies have reported on the prevalence of different symptoms and autonomic disorders in Long-COVID cohorts. Autonomic nervous system function, including both the parasympathetic and sympathetic limbs, has been studied using different testing techniques in Long-COVID patients. While numerous mechanisms may contribute to Long-COVID autonomic pathophysiology, it is currently unclear which ones lead to a Long-COVID presentation. To date, studies have not tested treatment options for autonomic disorders in Long-COVID patients.

Summary

Long-COVID is associated with autonomic abnormalities. There is a high prevalence of clinical autonomic disorders among Long-COVID patients, with limited knowledge of the underlying mechanisms and the effectiveness of treatment options.
Literature
1.
2.
Bozkurt B, Das SR, Addison D, et al. 2022 AHA / ACC key data elements and definitions for cardiovascular and noncardiovascular complications of COVID-19: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards. Circulation. 2022;80:388–465.
3.
4.
Dani M, Dirksen A, Taraborrelli P, Torocastro M, Panagopoulos D, Sutton R, Lim PB. Autonomic dysfunction in “long COVID”: rationale, physiology and management strategies. Clin Med (Northfield Il). 2021;21:63–7.CrossRef
5.
6.
7.
•• Rigo S, Barbic F, Khalaf K, et al. The Long-COVID autonomic syndrome in hospitalized patients: a one-year prospective cohort study. Eur J Intern Med. 2023; https://​doi.​org/​10.​1016/​j.​ejim.​2023.​08.​018. This study followed Long-COVID patients over 1 month, 3 months, 6 months, and 12 months. The researchers determined that Long-COVID patients were still experiencing symptoms at the 12 month mark despite indications of improvement at the 1 and 3 month marks.
8.
Ståhlberg M, Reistam U, Fedorowski A, et al. Post-COVID-19 tachycardia syndrome: a distinct phenotype of post-acute COVID-19 syndrome. Am J Med. 2021;134:1451–6.PubMedPubMedCentralCrossRef
9.
Raj SR. The postural tachycardia syndrome (POTS): pathophysiology, diagnosis & management. Indian Pacing Electrophysiol J. 2006;6:84–99.PubMedPubMedCentral
10.
Jamal SM, Landers DB, Hollenberg SM, Turi ZG, Glotzer TV, Tancredi J, Parrillo JE. Prospective evaluation of autonomic dysfunction in post-acute sequela of COVID-19. J Am Coll Cardiol. 2022;79:2325–30.PubMedPubMedCentralCrossRef
11.
Miglis MG, Prieto T, Shaik R, Muppidi S, Sinn D-I, Jaradeh S. A case report of postural tachycardia syndrome after COVID-19. Clin Auton Res. 2020;30:449–51.PubMedPubMedCentralCrossRef
12.
13.
14.
van Campen C(L)MC, Visser FC. Orthostatic intolerance in Long-Haul COVID after SARS-CoV-2: a case-control comparison with post-EBV and insidious-onset myalgic encephalomyelitis/chronic fatigue syndrome patients. Healthcare. 2022;10:1–12.
15.
Shah B, Kunal S, Bansal A, et al. Heart rate variability as a marker of cardiovascular dysautonomia in post-COVID-19 syndrome using artificial intelligence. Indian Pacing Electrophysiol J. 2022;22:70–6.PubMedPubMedCentralCrossRef
16.
Blitshteyn S, Whitelaw S. Postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders after COVID-19 infection: a case series of 20 patients. Immunol Res. 2021;69:205–11.PubMedPubMedCentralCrossRef
17.
Kanjwal K, Jamal S, Kichloo A, Grubb BP. New-onset postural orthostatic tachycardia syndrome following coronavirus disease 2019 infection. J Innov Card Rhythm Manag. 2020;11:4302–4.PubMedPubMedCentralCrossRef
18.
Reis Carneiro D, Rocha I, Habek M, Helbok R, Sellner J, Struhal W, Wenning G, Fanciulli A. Clinical presentation and management strategies of cardiovascular autonomic dysfunction following a COVID-19 infection – a systematic review. Eur J Neurol. 2023;30:1528–39.PubMedCrossRef
19.
Fanciulli A, Leys F, Krbot Skorić M, et al. Impact of the COVID-19 pandemic on clinical autonomic practice in Europe: a survey of the European Academy of Neurology and the European Federation of Autonomic Societies. Eur J Neurol. 2023;30:1712–26.CrossRef
20.
Desai AD, Boursiquot BC, Moore CJ, Gopinathannair R, Waase MP, Rubin GA, Wan EY. Autonomic dysfunction post–acute COVID-19 infection. Heart Case Rep. 2022;8:143–6.
21.
Johansson M, Ståhlberg M, Runold M, Nygren-Bonnier M, Nilsson J, Olshansky B, Bruchfeld J, Fedorowski A. Long-Haul Post–COVID-19 symptoms presenting as a variant of postural orthostatic tachycardia syndrome: the Swedish experience. JACC Case Rep. 2021;3:573–80.PubMedPubMedCentralCrossRef
22.
•• Hira R, Baker JR, Siddiqui T, et al. Objective hemodynamic cardiovascular autonomic abnormalities in post-acute sequelae of COVID-19. Can J Cardiol. 2023;39:767–75. This study reports on the prevalence of autonomic abnormalities in Long-COVID patients. The researchers implemented an active stand protocol that detected initial orthostatic hypotension in 61% of patients, which has not been reported before.PubMedCrossRef
23.
Stewart JM, Kota A, Donnell-smith MBO, Visintainer P, Terilli C, Medow MS. The preponderance of initial orthostatic hypotension in postural tachycardia syndrome. J Appl Physiol. 2023;129:459–66.CrossRef
24.
Sheldon RS, Grubb BP, Olshansky B, et al. 2015 Heart Rhythm Society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm. 2015;12:e41–63.PubMedPubMedCentralCrossRef
25.
• Shouman K, Vanichkachorn G, Cheshire WP, et al. Autonomic dysfunction following COVID-19 infection: an early experience. Clin Auton Res. 2021;31:385–94. This study was one of the first to implement a full autonomic function screening using a range of autonomic function tests in a Long-COVID cohort.PubMedPubMedCentralCrossRef
26.
Aranyó J, Bazan V, Lladós G, et al. Inappropriate sinus tachycardia in post-COVID-19 syndrome. Sci Rep. 2022;12:1–9.CrossRef
27.
28.
Buoite Stella A, Furlanis G, Frezza NA, Valentinotti R, Ajcevic M, Manganotti P. Autonomic dysfunction in post-COVID patients with and without neurological symptoms: a prospective multidomain observational study. J Neurol. 2022;269:587–96.PubMedCrossRef
29.
Sheikh NA, Phillips AA, Ranada S, et al. Mitigating initial orthostatic hypotension: mechanistic roles of muscle contraction versus sympathetic activation. Hypertension. 2022;79:638–47.PubMedCrossRef
30.
Monaghan A, Jennings G, Xue F, Byrne L, Duggan E, Romero-Ortuno R. Orthostatic intolerance in adults reporting Long COVID symptoms was not associated with postural orthostatic tachycardia syndrome. Front Physiol. 2022;13:1–11.CrossRef
31.
Brignole M, Moya A, De Lange FJ, et al. 2018 ESC Guidelines for the diagnosis and management of syncope. Eur Heart J. 2018;39:1883–948.PubMedCrossRef
32.
Rivasi G, Groppelli A, Brignole M, et al. Association between hypotension during 24h ambulatory blood pressure monitoring and reflex syncope: the SynABPM 1 study. Eur Heart J. 2022;43:3765–76.PubMedPubMedCentralCrossRef
33.
Sharad B, Rivasi G, Hamrefors V, Johansson M, Ungar A, Sutton R, Brignole M, Parati G, Fedorowski A. Twenty-four-hour ambulatory blood pressure profile in patients with reflex syncope and matched controls. J Am Heart Assoc. 2023;12:1–8.CrossRef
34.
Chou SHY, Beghi E, Helbok R, Moro E, Sampson J, Altamirano V, Mainali S, Bassetti C, Suarez JI, McNett M. Global incidence of neurological manifestations among patients hospitalized with COVID-19 - a report for the GCS-NeuroCOVID Consortium and the ENERGY Consortium. JAMA Netw Open. 2021;4:1–14.CrossRef
35.
Baker JR, Kimpinski K. Methods of laboratory evaluation of the autonomic nervous system in wakefulness and sleep. In: Chokroverty S, Cortelli P, editors. Auton. Nerv. Syst. Sleep, First. Springer; 2021. p. 79–98.CrossRef
36.
37.
Novak P, Mukerji SS, Alabsi HS, Systrom D, Marciano SP, Felsenstein D, Mullally WJ, Pilgrim DM. Multisystem involvement in post-acute sequelae of coronavirus disease 19 survey of autonomic symptoms. Am Neurol Assoc. 2022;91:367–79.CrossRef
38.
Milovanovic B, Djajic V, Bajic D, Djokovic A, Krajnovic T, Jovanovic S, Verhaz A, Kovacevic P, Ostojic M. Assessment of autonomic nervous system dysfunction in the early phase of infection with SARS-CoV-2 virus. Front Neurosci. 2021;15:1–14.CrossRef
39.
Ladlow P, O’Sullivan O, Houston A, et al. Dysautonomia following COVID-19 is not associated with subjective limitations or symptoms but is associated with objective functional limitations. Heart Rhythm. 2022;19:613–20.PubMedCrossRef
40.
• Rigo S, Urechie V, Diedrich A, Okamoto LE, Biaggioni I, Shibao CA. Impaired parasympathetic function in long-COVID postural orthostatic tachycardia syndrome - a case-control study. Bioelectron Med. 2023;9:1–9. The authors used spectral analyses to quantify sympathetic and parasympathetic activity among Long-COVID-POTS patients compared to healthy controls.CrossRef
41.
Bai T, Zhou D, Yushanjiang F, Wang D, Zhang D, Liu X, Song J, Zhang J, Hou X, Ma Y. Alternation of the autonomic nervous system is associated with pulmonary sequelae in patients with COVID-19 after six months of discharge. Front Physiol. 2022;12:1–14.CrossRef
42.
Marques KC, Silva CC, da Silva Trindade S, de Souza Santos MC, Rocha RSB, da Costa Vasconcelos PF, Quaresma JAS, Falcão LFM. Reduction of cardiac autonomic modulation and increased sympathetic activity by heart rate variability in patients with long COVID. Front Cardiovasc Med. 2022;9:1–10.CrossRef
43.
Zanin A, Amah G, Chakroun S, et al. Parasympathetic autonomic dysfunction is more often evidenced than sympathetic autonomic dysfunction in fluctuating and polymorphic symptoms of. Sci Reports. 2023;131(13):1–12.
44.
Mol MBA, Strous MTA, van Osch FHM, Jeroen Vogelaar F, Barten DG, Farchi M, Foudraine NA, Gidron Y. Heart-rate-variability (HRV), predicts outcomes in COVID-19. PLoS One. 2021;16:1–12.CrossRef
45.
Asarcikli LD, Hayiroglu Mİ, Osken A, Keskin K, Kolak Z, Aksu T. Heart rate variability and cardiac autonomic functions in post-COVID period. J Interv Card Electrophysiol. 2022;63:715–21.PubMedPubMedCentralCrossRef
46.
da Silva Menezes Junior A, Schröder AA, Botelho SM, Resende AL. Cardiac autonomic function in Long COVID-19 using heart rate variability: an observational cross-sectional study. J Clin Med. 2023;12:1–9.
47.
Karakayalı M, Artac I, Ilis D, Omar T, Rencuzogullari I, Karabag Y, Altunova M, Arslan A, Guzel E. Evaluation of outpatients in the post-COVID-19 period in terms of autonomic dysfunction and silent ischemia. Cureus. 2023;15:1–9.
48.
Zanin A, Amah G, Chakroun S, et al. Parasympathetic autonomic dysfunction is more often evidenced than sympathetic autonomic dysfunction in fluctuating and polymorphic symptoms of “long-COVID” patients. Sci Rep. 2023;13:8251.PubMedPubMedCentralCrossRef
49.
Chu H, Chan JF-W, Yuen TT-T, et al. Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study. Lancet Microbe. 2020;1:e14–23.PubMedPubMedCentralCrossRef
50.
Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci. 2020;11:995–8.PubMedCrossRef
51.
Franca RA, Ugga L, Guadagno E, Russo D, Del Basso De Caro M. Neuroinvasive potential of SARS-CoV2 with neuroradiological and neuropathological findings: is the brain a target or a victim? APMIS. 2021;129:37–54.PubMedCrossRef
52.
Meinhardt J, Radke J, Dittmayer C, et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci. 2020;242(24):168–75.
53.
54.
Peluso MJ, Lu S, Tang AF, et al. Markers of immune activation and inflammation in individuals with postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. J Infect Dis. 2021;224:1839–48.PubMedPubMedCentralCrossRef
55.
Ong SWX, Fong SW, Young BE, et al. Persistent symptoms and association with inflammatory cytokine signatures in recovered coronavirus disease 2019 patients. Open forum. Infect Dis. 2021;8:ofab156.
56.
Acosta-Ampudia Y, Monsalve DM, Rojas M, Rodriguez Y, Zapata E, Ramirez-Santana C, Anaya JM. Persistent autoimmune activation and proinflammatory state in post-coronavirus disease 2019 syndrome. J Infect Dis. 2022;225:2155–62.PubMedCrossRef
57.
Mueller SN, Rouse BT. Immune responses to viruses. In: Clin. Immunol. Elsevier; 2008. p. 421–31.CrossRef
58.
Craddock V, Mahajan A, Krishnamachary B, Spikes L, Chalise P, Dhillon NK. Persistent presence of spike protein and Viral RNA in the circulation of individuals with post-acute sequelae of COVID-19. medRxiv. 2022;95:e28568.
59.
60.
61.
62.
Hasty F, García G, Dávila CH, Wittels SH, Hendricks S, Chong S. Heart rate variability as a possible predictive marker for acute inflammatory response in COVID-19 patients. Mil Med. 2021;186:E34–8.PubMedPubMedCentralCrossRef
63.
Dotan A, Muller S, Kanduc D, David P, Halpert G, Shoenfeld Y. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev. 2021;20:102792.PubMedPubMedCentralCrossRef
64.
Ortona E, Malorni W. Long COVID: to investigate immunological mechanisms and sex/gender related aspects as fundamental steps for tailored therapy. Eur Respir J. 2022;59:2102245.PubMedPubMedCentralCrossRef
65.
66.
Wallukat G, Hohberger B, Wenzel K, Fürst J, Schulze-Rothe S, Wallukat A, Hönicke AS, Müller J. Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J Transl Autoimmun. 2021;4:100100.PubMedPubMedCentralCrossRef
67.
Fedorowski A. Postural orthostatic tachycardia syndrome: clinical presentation, aetiology and management. J Intern Med. 2019;285:352–66.PubMedCrossRef
68.
Yu X, Li H, Murphy TA, Nuss Z, Liles J, Liles C, Aston CE, Raj SR, Fedorowski A, Kem DC. Angiotensin II type 1 receptor autoantibodies in postural tachycardia syndrome. J Am Heart Assoc. 2018;7:e008351.PubMedPubMedCentralCrossRef
69.
Fedorowski A, Li H, Yu X, et al. Antiadrenergic autoimmunity in postural tachycardia syndrome. Europace. 2017;19:1211–9.PubMedCrossRef
70.
71.
Finucane C, van Wijnen VK, Fan CW, et al. A practical guide to active stand testing and analysis using continuous beat-to-beat non-invasive blood pressure monitoring. Clin Auton Res. 2019;29:427–41.PubMedCrossRef
72.
Wieling W, Krediet CTP, Van Dijk N, Linzer M, Tschakovsky ME. Initial orthostatic hypotension: review of a forgotten condition. Clin Sci (Lond). 2007;112:157–65.PubMedCrossRef
73.
Raj SR, Arnold AC, Barboi A, Claydon VE, Limberg JK, Lucci VM, Numan M, Peltier A, Snapper H, Vernino S. Long-COVID postural tachycardia syndrome: an American Autonomic Society statement. Clin Aut Res. 2021;31:365–8.CrossRef
74.
Green EA, Raj V, Shibao CA, Biaggioni I, Black BK, Dupont WD, Robertson D, Raj SR. Effects of norepinephrine reuptake inhibition on postural tachycardia syndrome. J Am Heart Assoc. 2013;2:1–9.CrossRef
75.
Schroeder C, Tank J, Boschmann M, Diedrich A, Sharma AM, Biaggioni I, Luft FC, Jordan J. Selective norepinephrine reuptake inhibition as a human model of orthostatic intolerance. Circulation. 2002;105:347–53.PubMedCrossRef
76.
Vincent S, Bieck PR, Garland EM, Loghin C, Bymaster FP, Black BK, Gonzales C, Potter WZ, Robertson D. Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles. Circulation. 2004;109:3202–7.PubMedCrossRef
77.
Fedorowski A, Olsén MF, Nikesjö F, Janson C, Bruchfeld J, Lerm M, Hedman K. Cardiorespiratory dysautonomia in post-COVID-19 condition: Manifestations, mechanisms and management. J Intern Med. 2023;294:548–62.PubMedCrossRef
78.
Raj SR, Guzman JC, Harvey P, Richer L, Schondorf R, Seifer C, Thibodeau-Jarry N, Sheldon RS. Canadian Cardiovascular Society position statement on postural orthostatic tachycardia syndrome (POTS) and related disorders of chronic orthostatic intolerance. Can J Cardiol. 2020;36:357–72.PubMedCrossRef
79.
Raj SR, Fedorowski A, Sheldon RS. Diagnosis and management of postural orthostatic tachycardia syndrome. Can Med Assoc J. 2022;194:E378–85.CrossRef
80.
Garland EM, Gamboa A, Nwazue VC, et al. Effect of high dietary sodium intake in patients with postural tachycardia syndrome. J Am Coll Cardiol. 2021;77:2174–84.PubMedPubMedCentralCrossRef
81.
Bourne KM, Sheldon RS, Hall J, et al. Compression garment reduces orthostatic tachycardia and symptoms in patients with postural orthostatic tachycardia syndrome. J Am Coll Cardiol. 2021;77:285–96.PubMedCrossRef
82.
Fernandes T, Baraúna VG, Negrão CE, Ian Phillips M, Oliveira EM. Aerobic exercise training promotes physiological cardiac remodeling involving a set of microRNAs. Am J Physiol Heart Circ Physiol. 2015;309:H543–52.PubMedPubMedCentralCrossRef
83.
Gibbons CH, Silva G, Freeman R. Cardiovascular exercise as a treatment of postural orthostatic tachycardia syndrome: a pragmatic treatment trial. Heart Rhythm. 2021;18:1361–8.PubMedCrossRef
84.
Raj SR. Row, row, row your way to treating postural tachycardia syndrome. Heart Rhythm. 2016;13:951–2.PubMedCrossRef
85.
Sheikh NA, Ranada S, Lloyd M, et al. Lower body muscle preactivation and tensing mitigate symptoms of initial orthostatic hypotension in young females. Heart Rhythm. 2022;19:604–10.PubMedCrossRef
86.
Raj SR, Black BK, Biaggioni I, Paranjape SY, Ramirez M, Dupont WD, Robertson D. Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome: less is more. Circulation. 2009;120:725–34.PubMedPubMedCentralCrossRef
87.
Arnold AC, Okamoto LE, Diedrich A, Paranjape SY, Raj SR, Biaggioni I, Gamboa A. Low-dose propranolol and exercise capacity in postural tachycardia syndrome a randomized study. Neurology. 2013;80:1927–33.PubMedPubMedCentralCrossRef
88.
Taub PR, Zadourian A, Lo HC, Ormiston CK, Golshan S, Hsu JC. Randomized trial of ivabradine in patients with hyperadrenergic postural orthostatic tachycardia syndrome. J Am Coll Cardiol. 2021;77:861–71.PubMedCrossRef
89.
Raj SR, Black BK, Biaggioni I, Harris PA, Robertson D. Acetylcholinesterase inhibition improves tachycardia in postural tachycardia syndrome. Circulation. 2005;111:2734–40.PubMedCrossRef
90.
Kanjwal K, Karabin B, Sheikh M, Elmer L, Kanjwal Y, Saeed B, Grubb BP. Pyridostigmine in the treatment of postural orthostatic tachycardia: a single-center experience. Pacing Clin Electrophysiol. 2011;34:750–5.PubMedCrossRef
91.
Coffin ST, Black BK, Biaggioni I, Paranjape SY, Orozco C, Black PW, Dupont WD, Robertson D, Raj SR. Desmopressin acutely decreases tachycardia and improves symptoms in the postural tachycardia syndrome. Heart Rhythm. 2012;9:1484–90.PubMedPubMedCentralCrossRef
92.
Sheldon R, Raj SR, Rose MS, et al. Fludrocortisone for the prevention of vasovagal syncope: a randomized, placebo-controlled trial. J Am Coll Cardiol. 2016;68:1–9.PubMedCrossRef
93.
Annamaria M, Lupo PP, Foresti S, De Ambroggi G, de Ruvo E, Sciarra L, Cappato R, Calo L. Treatment of inappropriate sinus tachycardia with ivabradine. J Interv Card Electrophysiol. 2016;46:47–53.PubMedCrossRef
94.
Shabtaie SA, Witt CM, Asirvatham SJ. Efficacy of medical and ablation therapy for inappropriate sinus tachycardia: a single-center experience. J Cardiovasc Electrophysiol. 2021;32:1053–61.PubMedCrossRef
95.
Brignole M, Menozzi C, Moya A, et al. Pacemaker therapy in patients with neurally mediated syncope and documented asystole: third international study on syncope of uncertain etiology (ISSUE-3): a randomized trial. Circulation. 2012;125:2566–71.PubMedCrossRef
96.
Trahair LG, Horowitz M, Jones KL. Postprandial hypotension: a systematic review. J Am Med Dir Assoc. 2014;15:394–409.PubMedCrossRef
97.
Kaufmann H, Freeman R, Low P, Pedder S, Hewitt LA, Mauney J, Feirtag M, Mathias CJ. Droxidopa for neurogenic orthostatic hypotension. Neurology. 2014;83:328–35.PubMedPubMedCentralCrossRef
98.
Veazie S, Peterson K, Ansari Y, Chung KA, Gibbons CH, Raj SR, Helfand M. Fludrocortisone for orthostatic hypotension. Cochrane database Syst Rev. 2021;5:CD012868.PubMed
Metadata
Title
Autonomic Manifestations of Long-COVID Syndrome
Authors
Rashmin Hira
Kavithra Karalasingham
Jacquie R. Baker
Satish R. Raj
Publication date
10-11-2023
Publisher
Springer US
Published in
Current Neurology and Neuroscience Reports / Issue 12/2023
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-023-01320-z

Other articles of this Issue 12/2023

Current Neurology and Neuroscience Reports 12/2023 Go to the issue

Review

Recent Developments in Blood Biomarkers in Neuro-oncology

Review

Exploring the Role of Locus Coeruleus in Alzheimer’s Disease: a Comprehensive Update on MRI Studies and Implications

Review

Neurotoxicity of cancer immunotherapies

Review

Disparities in Neuro-Oncology

Review

Advances in pediatric medulloblastoma

Review

Advances in Treatment of Diffuse Midline Gliomas